

INFORMATION DISCLOSURE		ATTY. DOCKET NO.	SERIAL NO.
CITATION		620-439	10/579,230
		APPLICANT	
(Use several sheets if necessary)		VELDMAN et al.	
		FILING DATE	GROUP
		May 12, 2006	unknown

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
1	4,416,872	11/1983	Alving			
2	5,013,556	05/1991	Woolde			
3	5,213,804	05/1993	Martin			
4	5,395,619	03/1995	Zalipsky			
5	5,527,528	06/1996	Allen			
6	5,800,833	09/1998	Hope			
7	2002/0119990	08/2002	Madden			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	TRANSLATION		
			CLASS	SUBCLASS	YES NO
8 WO 88/01171	02/1988	WIPO			
9 WO 99/41266	08/1999	WIPO			
10 WO 02/02077	01/2002	WIPO			
11 EP 0 896 816	02/1999	Europe			
12 JP 8-034746	02/1996	Japan			X

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

13	Abraham SA, et al, 2002, "Formation of transition metal-doxorubicin complexes inside liposomes," <i>Biochim. Biophys. Acta.</i> , Vol. 1565(1), pp. 41-54.
14	Bai J, et al, 1997, "Measurement of spontaneous transfer and transbilayer movement of BODIPY-labeled lipids in lipid vesicles," <i>Biochemistry</i> , Vol. 36, pp. 8840-8848.
15	Bligh EJ, et al, 1959, "A rapid method of total lipid extraction and purification," <i>Can. J. Biochem. Physiol.</i> , Vol. 37, pp. 911-917.
16	Carmichael J, et al, 1987, "Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing," <i>Cancer Res.</i> , Vol. 47, pp. 936-942.
17	Cheung BC, et al, 1998, "Loading of doxorubicin into liposomes by forming Mn ²⁺ -drug complexes," <i>Biochim. Biophys. Acta.</i> , Vol. 1414(1-2), pp. 205-216.
18	Druckmann S, et al, 1989, "Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma: implications for pharmacokinetic studies," <i>Biochim. Biophys. Acta</i> , Vol. 980, pp. 381-384.
19	Everts M, et al, 2003, "In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium," <i>Pharm. Res.</i> , Vol. 20, pp. 64-72.
20	Gabizon A, 2001, "Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy," <i>Cancer Inv.</i> , Vol. 19, pp. 424-436.

*Examiner /Michael Henry/ Date Considered 01/02/2010

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A520 (Also PTO-1449)

INFORMATION DISCLOSURE		ATTY. DOCKET NO.	SERIAL NO.
CITATION		620-439 APPLICANT	10/579,230
(Use several sheets if necessary)		VELDMAN et al.	
		FILING DATE	GROUP
		May 12, 2006	unknown
OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)			
21	Gabizon A, et al, 1996, "Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines," <u>J. Drug Target</u> , Vol. 3, pp. 391-398.		
22	Ghidoni R, et al, 1999, "Use of sphingolipid analogs: benefits and risks," <u>Biochim. Biophys. Acta</u> , Vol. 1439, pp. 17-39.		
23	Haran G, et al Y, 1993, "Transmembrane ammonium sulphate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases," <u>Biochim. Biophys. Acta</u> , Vol. 1151, pp. 201-215.		
24	Harasym TO, et al, 1997, "Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/ cholesterol liposomes," <u>Cancer Chemother. Pharmacol.</u> , Vol. 40, pp. 309-317.		
25	Heijn M, et al, 1999, "Cellular membrane permeability of anthracyclines does not correlate with their delivery in a tissue-isolated tumor," <u>Cancer Res.</u> , Vol. 59, pp. 4458-4463.		
26	Horowitz AT, et al, 1992, "In vitro cytotoxicity of liposome-encapsulated doxubicin: dependence on liposome composition and drug release," <u>Biochim. Biophys. Acta</u> , Vol. 1109, pp. 203-209.		
27	Jeckel D, et al, 1993, "Truncated ceramide analogs as probes for sphingolipid biosynthesis and transport," <u>Adv. Lipid Res.</u> , Vol. 26, pp. 143-160.		
28	Koning GA, et al, 1999, "Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells," <u>Br. J. Cancer</u> , Vol. 80, pp. 1718-1725.		
29	Koning GA, et al, 2003, "Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer Cells. An in vitro comparison," <u>Pharm. Res.</u> , Vol. 20, pp. 1249-1257.		
30	Koning, G.A., et al, 2003, "Short-chain liposomal sphingolipids potentiate in vitro doxorubicin cytotoxicity by enhancing its cellular influx," Conference Abstract for Liposome Advances: Progress in Drug and Vaccine Delivery, 15-19 December 2003, London, UK.		
31	Lasic DD, et al, 1995, "Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery," <u>Biochim. Biophys. Acta</u> , Vol. 1239(2), pp. 145-156.		
32	Lothstein L, et al, 2001, "Anthracyclin drug targeting: cytoplasmic versus nuclear - a fork in the road," <u>Drug Res. Updates</u> , Vol. 4, pp. 169-177.		
33	Mabrey, S., et al, 1978, "High-sensitivity scanning calorimetric study of mixtures of cholesterol with dimyristoyl- and dipalmitoylphosphatidylcholines", <u>Biochem.</u> , Vol. 17, pp. 2464-2468.		
34	Martin, F.J., 1990, "Pharmaceutical Manufacturing of Liposomes", <u>Specialized Drug Delivery Systems - Manufacturing and Production Technology</u> , pp. 267-316.		
*Examiner		/Michael Henry/	
		Date Considered	
		01/02/2010	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.C.H./

INFORMATION DISCLOSURE		ATTY. DOCKET NO.	SERIAL NO.
CITATION		620-439	10/579,230
		APPLICANT	
(Use several sheets if necessary)		VELDMAN et al.	
		FILING DATE	GROUP
		May 12, 2006	unknown

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

35	Mayer, L.D., et al, 1986, "Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient", <u>Biochim. Biophys. Acta</u> , Vol. 857, pp. 123-126.
36	Mayer, L.D., et al., 1989, "Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in Mice", <u>Cancer Res.</u> , Vol. 49, pp. 5922-5930.
37	Olson, F., et al, 1979, "Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes", <u>Biochim. Biophys. Acta</u> , Vol. 557, pp. 9-23.
38	Pan, XQ, et al, 2003, "Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model," <u>Pharm. Res.</u> , Vol. 20, pp. 417-422.
39	Park, JW, et al, 2002, "Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery," <u>Clin. Cancer Res.</u> , Vol. 8, pp. 1172-1181.
40	Robert J, et al, 1993, "Pharmacokinetics and metabolism of anthracyclines," in <u>Cancer Surveys</u> , Vol. 17, pp. 219-252.
41	Rouser G, et al, 1970, "Two-dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots," <u>Lipids</u> , Vol. 5, pp. 494-496.
42	Silence, D.J., et al., 2000, "Assay for the transbilayer distribution of glycolipids: selective oxidation of glucosylceramide to glucuronylceramide by TEMPO nitroxyl radicals", <u>Journal of Lipid Research</u> , Vol. 41, pp. 1252-1260.
43	Smith PK, et al, 1985, "Measurement of protein using bicinchoninic acid," <u>Anal. Chem.</u> , Vol. 57, pp. 76-85.
44	Speth PA, et al, 1988, "In vivo cellular adriamycin concentrations related to growth inhibition of normal and leukemic human bone marrow cells," <u>Eur. J. Cancer Clin. Oncol.</u> , Vol. 24, pp. 667-674.
45	Storm G, et al, 1985, "The interaction of cytostatic drugs with adsorbents in aqueous media. The potential implications for liposome preparation", <u>Biochim. Biophys. Acta</u> , Vol. 818, pp. 343-351.
46	Szoka, F., Jr., et al, 1980, "Comparative properties and methods of preparation of lipid vesicles (liposomes)", <u>Ann. Rev. Biophys. Biogen.</u> , Vol. 9, p. 457.
47	Tardi PG, et al, 1996, "Liposomal doxorubicin," <u>J. Drug Target</u> , Vol. 4, pp. 129-140.
48	Tsong, T.Y., 1975, "Effect of phase transition on the kinetics of dye transport in phospholipid bilayer structures", <u>Biochem.</u> , Vol. 14, pp. 5409-5414; pp. 5415-5417.
49	Tubaro, E., et al, 1995, "Effect of a new de-N-acetyl-lysoglycosphingolipid on some tumour models," <u>European Journal of Pharmacology</u> , Vol. 294, pp. 555-563.
50	Uster PS, et al, 1996, "Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time," <u>FEBS Lett.</u> , Vol. 386, pp. 243-246.

*Examiner

/Michael Henry/

Date Considered

01/02/2010

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.C.H./

1121812

*Examiner /Michael Henry/ Date Considered 01/02/2010

Examiner: Initial if reference considered; whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.C.H./